biOasis Technologies Inc
XTSX:BTI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
biOasis Technologies Inc
Common Stock
biOasis Technologies Inc
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
biOasis Technologies Inc
XTSX:BTI
|
Common Stock
CA$28.8m
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
9%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Common Stock
CA$123.2m
|
CAGR 3-Years
66%
|
CAGR 5-Years
163%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Common Stock
$1.1B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
16%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Common Stock
$1.6B
|
CAGR 3-Years
14%
|
CAGR 5-Years
32%
|
CAGR 10-Years
27%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Common Stock
CA$225.1m
|
CAGR 3-Years
35%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Common Stock
$513.3m
|
CAGR 3-Years
95%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
biOasis Technologies Inc
Glance View
biOasis Technologies, Inc. operates as a biopharmaceutical company. The company is headquartered in Richmond British Columbia, British Columbia. The company went IPO on 2007-07-24. The firm is engaged in the development of the xB3 platform, a technology for the delivery of therapeutics across the blood brain barrier (BBB) and the treatment of central nervous system (CNS) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. xB3 is based on a human transport protein found circulating at low levels in the blood. The xB3 platform has an efficacy in its ability to shuttle molecules across the blood-brain barrier and reach its targets within the brain through a process called receptor-mediated transcytosis. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.
See Also
What is biOasis Technologies Inc's Common Stock?
Common Stock
28.8m
CAD
Based on the financial report for Nov 30, 2022, biOasis Technologies Inc's Common Stock amounts to 28.8m CAD.
What is biOasis Technologies Inc's Common Stock growth rate?
Common Stock CAGR 10Y
9%
Over the last year, the Common Stock growth was 5%. The average annual Common Stock growth rates for biOasis Technologies Inc have been 4% over the past three years , 5% over the past five years , and 9% over the past ten years .
